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Abstract
BACKGROUND
The management of proximal esophageal cancer differs from that of tumors
located in the mid and lower part of the esophagus due to the close vicinity of
vital structures. Non-surgical treatment options like radiotherapy and definitive
chemoradiation (CRT) have been implemented. The trends in (non-)surgical
treatment and its impact on overall survival (OS) in patients with proximal
esophageal cancer are unclear, related to its rare disease status. To optimize
treatment strategies and counseling of patients with proximal esophageal cancer,
it is therefore essential to gain more insight through real-life studies.
AIM
To establish trends in treatment and OS in patients with proximal esophageal
cancer.
METHODS
In this population-based study, patients with proximal esophageal cancer
diagnosed between 1989 and 2014 were identified in the Netherlands Cancer
Registry. The proximal esophagus consists of the cervical esophagus and the
upper thoracic section, extending to 24 cm from the incisors. Trends in
radiotherapy, chemotherapy, and surgery, and OS were assessed. Analyses were
stratified by presence of distant metastasis. Multivariable Cox proportional
hazards regression analyses was performed to assess the effect of period of
diagnosis on OS, adjusted for patient, tumor, and treatment characteristics.
RESULTS
In total, 2783 patients were included. Over the study period, the use of
radiotherapy, resection, and CRT in non-metastatic disease changed from 53%,
23%, and 1% in 1989-1994 to 21%, 9%, and 49% in 2010-2014, respectively. In
metastatic disease, the use of chemotherapy and radiotherapy increased over
time. Median OS of the total population increased from 7.3 mo [95% confidence
interval (CI): 6.4-8.1] in 1989-1994 to 9.5 mo (95%CI: 8.1-10.8) in 2010-2014
(logrank P < 0.001). In non-metastatic disease, 5-year OS rates improved from 5%
(95%CI: 3%-7%) in 1989-1994 to 13% (95%CI: 9%-17%) in 2010-2014 (logrank P <
0.001). Multivariable regression analysis demonstrated a significant treatment
effect over time on survival. In metastatic disease, median OS was 3.8 mo (95%CI:
2.5-5.1) in 1989-1994, and 5.1 mo (95%CI: 4.3-5.9) in 2010-2014 (logrank P = 0.26).
CONCLUSION
OS significantly improved in non-metastatic proximal esophageal cancer, likely
to be associated with an increased use of CRT. Patterns in metastatic disease did
not change significantly over time.
Key words: Esophagus; Esophageal cancer; Proximal; Cervical; Upper thoracic; Trends;
Treatment; Survival; Outcome
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Proximal esophageal cancer is a rare disease, accounting for only 10% of all
esophageal cancer cases. Limited data on treatment and survival in this rare tumor have
been published, restricting patient counseling. The present investigation is the largest
population-based cohort study evaluating trends in treatment and survival in proximal
esophageal cancer. This study represents daily clinical practice, showing improvement in
overall survival in patients with non-metastatic proximal esophageal cancer, with a shift
to non-surgical treatment.
Citation: de Vos-Geelen J, Geurts SME, van Putten M, Valkenburg-van Iersel LBJ, Grabsch HI,
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INTRODUCTION
Esophageal cancer is the seventh most common cancer worldwide[1]. Although the
absolute number of deaths has decreased, esophageal cancer is still the sixth leading
cause  of  cancer-related mortality  globally[1].  Surgical  treatment  of  patients  with
esophageal cancer, and in particular treatment of cancer located in the proximal part
of the esophagus, is challenging because of the close proximity to vital structures. The
proximal  part  of  the  esophagus  consists  of  the  cervical  and  the  upper  thoracic
segment. Proximal esophageal cancer is relatively uncommon, accounting for 10% of
all esophageal cancer cases[2].
The management of proximal esophageal cancer differs from that of tumors located
in the mid and lower part of the esophagus. Patients with proximal esophageal cancer
often present with locally advanced disease, for which potentially curative surgery
would require extensive mutilating resections, with a high risk of major complications
and a significant impact on patients quality of life. To prolong survival and improve
quality  of  life,  non-surgical  treatment  options  like  radiotherapy  and  definitive
chemoradiation (CRT)  have been explored since  the  1990s,  following promising
treatment results of cancers in the thoracic esophagus, hypopharynx, and non-small-
cell lung cancer[3-6]. In a meta-analysis in 2006, Wong et al. showed that the addition of
chemotherapy to  radiotherapy for  the definitive treatment  of  esophageal  cancer
significantly increased response and overall survival (OS) rates[7].
Therefore, definitive CRT is recommended as treatment modality for patients with
non-metastatic proximal esophageal cancer[8,9]. However, only four of the 19 studies in
the aforementioned meta-analysis incorporated patients with proximal esophageal
cancers, limiting the extrapolation of these findings to the proximal esophagus.
Separate OS rates for patients with proximal esophageal cancer are largely lacking
from clinical trials, due to exclusion of this subpopulation or related to its rare disease
status. To optimize treatment strategies and counseling of patients with proximal
esophageal  cancer,  it  is  therefore  essential  to  gain  more  insight  in  patient
characteristics, provided therapies and OS through real-life studies.
The  aim of  this  population-based cohort  study was  to  establish  the  trends  in
treatment and OS in patients diagnosed with non-metastatic or metastatic proximal
esophageal cancer in a nationwide registry between 1989 and 2014.
MATERIALS AND METHODS
Patients
All  patients  with  a  tumor  located  in  the  cervical  or  upper  thoracic  esophagus
diagnosed between 1989 and 2014 were identified in the Netherlands Cancer Registry
(NCR).  The  NCR  is  a  population-based  cancer  registry  of  all  residents  of  the
Netherlands.  The NCR is  linked to the national  automated pathological  archive,
which leads to the automatic inclusion of all newly diagnosed malignancies in the
Netherlands. Additional data sources linked to the NCR are the national hospital
discharge register and registers of radiotherapy institutions. Information on vital
status  was  obtained through annual  linkage with  the  Municipal  Administrative
Database, in which all  deceased or emigrated individuals in the Netherlands are
registered. This study was approved by the Privacy Review Board of the NCR and the
need  for  a  separate  approval  from an  ethics  committee  in  the  Netherlands  was
waived.
Definitions
Topography and histology were coded according to the International Classification of
Diseases for Oncology (ICD-O)[10]. ICD-O histology codes were used to classify tumors
as squamous cell carcinoma (SCC), adenocarcinoma, and other origin. Cancers of the
proximal  esophagus  can  be  subdivided  in  cancers  originating  in  the  cervical
esophagus  (CEC,  ICD-O C15.0),  commencing  at  the  lower  border  of  the  cricoid
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cartilage and ending at the thoracic inlet, approximately 18 cm from the incisors, and
cancers  in  the  upper  thoracic  section (UTEC,  ICD-O C15.3),  extending from the
thoracic inlet to the level of the tracheal bifurcation, which is approximately 24 cm
from the incisors[11].
Tumor staging was registered according to the Union for International Cancer
Control  TNM  classification  that  was  valid  at  the  time  of  diagnosis.  As  the
classification of tumor stage (cT) was reasonably comparable from the TNM-4 to -6,
but changed with the introduction of the 7th edition in 2010, we converted all tumor
and lymph node stages according to TNM-6th edition. Patients with a cM1a tumor
according to TNM-6th  edition, defined as cervical lymph node involvement, were
categorized as having a positive lymph node status (cN+). Patients with unknown
metastatic status (cMx) were included in the non-metastatic group.
All treatments for the primary disease stage were registered. Treatment categories
included  resection,  neoadjuvant  treatment  and  resection,  radiotherapy,
chemotherapy, radiotherapy and chemotherapy, other treatment, and no (anti-cancer)
treatment.  Resection  included  patients  who  received  a  surgical  resection  or  an
endoscopic excision (n = 20). The group of “neoadjuvant and resection” comprised
patients who underwent a resection, preceded by radiotherapy, chemotherapy or
with concurrent CRT. The group “radiotherapy and chemotherapy” included patients
who were treated with sequential or concurrent radiotherapy and chemotherapy,
without any resection. Other treatments were not otherwise specified (palliative)
treatments. “Other treatment” and “no (anti-cancer) treatment” were summarized as
“no localized treatment”. Type of surgical treatment and details on chemotherapy or
radiotherapy were not collected by the data clerks of the NCR.
Five-year periods of diagnosis were defined: 1989-1994, 1995-1999, 2000-2004, 2005-
2009, and 2010-2014.
Statistical analysis
OS was calculated by period of diagnosis using the Kaplan-Meier method and a
comparison between groups was made using the log-rank test. OS was defined as the
time from diagnosis to death from any cause, censored at last follow-up date or until
February 1, 2017. The median follow-up time was calculated using the reverse Kaplan
Meier method (death censored). Multivariable Cox proportional hazards regression
analyses were performed to assess the effect of period of diagnosis on OS, adjusted for
age,  histological  type,  tumor  location,  cT  category,  cN category,  and  treatment
modality.  Variance  inflation  factors  were  calculated  to  assess  the  degree  of
multicollinearity among the independent variables in the Cox proportional hazard
model. Analyses were stratified by the presence of metastatic disease (cM0 vs cM1),
tumor location (CEC vs UTEC), and histological type (SCC vs adenocarcinoma). As
the interaction analysis did not show any difference in OS between tumor location,
i.e., cervical or upper thoracic site, and histology, results are presented by presence or
absence of metastatic disease.
The statistical review of the study was performed by two senior epidemiologists.
RESULTS
Study population
We  identified  2783  patients  diagnosed  with  proximal  esophageal  cancer  in  the
Netherlands between 1989 and 2014 (Table 1).  The median follow-up time of  all
patients was 103 mo [95% confidence interval (CI): 91-117 mo]. Fifty-six percent of
patients  were  male,  and  47%  were  between  60  and  74  years  old  at  the  time  of
diagnosis.  In  total,  81% of  cancers  were  SCC.  Two percent  of  the  patients  were
diagnosed with clinical stage 1, 20% with stage 2, 28% with stage 3, 21% with stage 4,
and 29% with unknown stage disease. The number of patients with unknown stage
disease decreased over time. In 2010-2014, 27% of patients had been diagnosed with
another malignancy prior to the diagnosis of proximal esophageal cancer (data not
shown).
Trends in treatment in patients with proximal esophageal cancer
In patients with non-metastatic disease, the proportion of patients treated with CRT
alone increased from 1% in 1989-1994 to 49% in 2010-2014 (Figure 1A). Resection
without neoadjuvant treatment was performed in 17% of patients in 1989-1994 and in
2% of patients in 2010-2014. The proportion of patients treated with neoadjuvant
therapy and resection was relatively constant over time, varying between 3% and 7%.
The proportion of patients with non-metastatic proximal esophageal cancer that did
not undergo any form of treatment varied between 15% and 22%, without a clear
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Table 1  Patient and tumor charactistics by time period of diagnosis, n (%)
Charactistics Total (n = 2783) 1989-1994 (n = 484) 1995-1999 (n = 499) 2000-2004 (n = 552) 2005-2009 (n = 583) 2010-2014 (n = 665)
Sex
Male 1562 (56) 259 (54) 263 (53) 308 (56) 344 (59) 388 (58)
Female 1221 (44) 225 (46) 236 (47) 244 (44) 239 (41) 277 (42)
Age (yr)
< 60 725 (26) 140 (29) 148 (30) 178 (32) 128 (22) 131 (20)
60-74 1304 (47) 194 (40) 219 (44) 223 (40) 301 (52) 367 (55)
≥ 75 754 (27) 150 (31) 132 (26) 151 (27) 154 (26) 167 (25)
Histology
SCC 2248 (81) 382 (79) 390(78) 440 (80) 480 (82) 556 (84)
Adenocarcino-
ma
320 (11) 62 (13) 63 (13) 70 (13) 61 (10) 64 (10)
Other 215 (8) 40 (8) 46 (9) 42 (8) 42 (7) 45 (7)
Tumor location
CEC 648 (23) 138 (29) 138 (28) 154 (28) 126 (22) 92 (14)
UTEC 2135 (77) 346 (71) 361 (72) 398 (72) 457 (78) 573 (86)
cT classification
cT1 81 (3) 17 (4) 16 (3) 12 (2) 16 (3) 20 (3)
cT2 236 (8) 12 (2) 16 (3) 36 (7) 48 (8) 124 (19)
cT3 447 (16) 36 (7) 39 (8) 79 (14) 109 (19) 184 (28)
cT4 665 (24) 115 (24) 123 (25) 161 (29) 147 (25) 119 (18)
cTx 1354 (49) 304 (63) 305 (61) 264 (48) 263 (45) 218 (33)
cN classification
cN0 892 (32) 172 (36) 173 (35) 189 (34) 157 (27) 201 (30)
cN+ 1193 (43) 119 (25) 158 (32) 208 (38) 313 (54) 395 (59)
cNx 698 (25) 193 (40) 168 (34) 155 (28) 113 (19) 69 (10)
cM classification
cM0 1752 (63) 311 (64) 314 (63) 316 (57) 344 (59) 467 (70)
cM1 589 (21) 79 (16) 88 (18) 96 (17) 135 (23) 191 (29)
cMx 442 (16) 94 (19) 97 (19) 140 (25) 104 (18) 7 (1)
TNM stage
1 64 (2) 14 (3) 14 (3) 9 (2) 14 (2) 13 (2)
2 565 (20) 80 (17) 72 (14) 100 (18) 125 (22) 188 (28)
3 763 (27) 102 (21) 126 (25) 173 (31) 174 (30) 188 (28)
4 589 (21) 79 (16) 88 (18) 96 (17) 135 (23) 191 (29)
Unknown 802 (29) 209 (43) 199 (40) 174 (32) 135 (23) 85 (13)
Percentages may not add up to 100 percent because of rounding. SCC: Squamous cell carcinoma; CEC: Cervical esophageal cancer; UTEC: Upper thoracic
esophageal cancer.
trend over time.
For  patients  with metastatic  disease,  only minor  variations  in  treatment  were
observed (Figure 1B). Fourty-four percent of patients were treated with radiotherapy
alone  in  1989-1994,  which  slightly  decreased  to  37%  in  2010-2014.  Over  time,
multimodal treatment of chemotherapy and radiotherapy, concurrent or sequential,
was administered more frequently: In 3% of patients in 1989-1994 and 23% of patients
in  2010-2014.  Chemotherapy  alone  was  given  to  7%-12% of  patients  in  all  time
periods. The proportion of patients diagnosed with metastatic proximal esophageal
cancer who did not undergo any form of anti-cancer treatment decreased from 33% in
1989-2004 to 24% in 2010-2014.
Trends in survival in patients with proximal esophageal cancer
The median OS of the total population of patients with proximal esophageal cancer
was 8.0 mo (95%CI: 7.6-8.5 mo). Median OS increased over the study period, from 7.3
mo (95%CI: 6.4-8.1 mo) in 1989-1994, to 9.5 mo (95%CI: 8.1-10.8 mo) in 2010-2014
(logrank P < 0.001) (Figure 2). In patients with non-metastatic proximal esophageal
cancer, 1- and 5-year OS rates improved from 30% (95%CI: 26%-34%) and 5% (95%CI:
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Figure 1
Figure 1  Treatment of patients with proximal esophageal cancer in the Netherlands between 1989 and 2014. A: Patients with non-metastatic proximal
esophageal cancer; B: Patients with metastatic proximal esophageal cancer.
3%-7%) in 1989-1994, to 44% (95%CI: 40%-48%) and 13% (95%CI: 9%-17%) in 2010-
2014, respectively (logrank P < 0.001) (Figure 3A). Median OS of patients with non-
metastatic proximal esophageal cancer was 8.0 mo (95%CI: 7.0-8.9 mo) in 1989-1994
and 13.3 mo (95%CI: 11.1-15.5 mo) in 2010-2014. Patients with stage 1 disease showed
the most favorable outcome with a 1- and 5-year OS rate of 70% (95%CI: 57%-80%)
and 22% (95%CI 13%-34%), compared with 50% (95%CI: 46%-54%) and 15% (95%CI:
12%-18%) in stage 2, and 35% (95%CI: 32%-38%) and 10% (95%CI: 8%-13%) in stage 3
disease, respectively (logrank P < 0.001) (Supplementary Figure 1).
In patients with non-metastatic proximal esophageal cancer, univariable analysis
showed that period of diagnosis, age, histological type, cT, cN, and treatment were all
associated with OS (Table 2). OS was similar for patients diagnosed with CEC or
UTEC. Multivariable  Cox regression analysis  adjusted for  age,  histological  type,
tumor location, cT, and cN demonstrated an OS benefit for patients diagnosed in
2005-2009 [Hazard ratio (HR) = 0.77, P < 0.001] or 2010-2014 (HR = 0.72, P < 0.001)
when compared with patients diagnosed in 1989-1994. However, the time period
effect  disappeared  after  additional  inclusion  of  treatment  modality  in  the
multivariable model. All treatment modalities had a statistically significant effect on
OS compared with no localized treatment (P < 0.001). Patients with non-metastatic
proximal  esophageal  cancer  treated  with  surgery  with  or  without  neoadjuvant
therapy or treated with definitive CRT showed 5-year OS rates of 31% (95%CI: 23%-
40%), 21% (95%CI: 16%-28%), and 22% (95%CI: 19%-26%), respectively (logrank P =
0.32) (Supplementary Figure 2).
In patients  with metastatic  disease,  OS did not  change significantly over time
(logrank P = 0.26) (Figure 3B). Median OS was 3.8 mo (95%CI: 2.5-5.1 mo) in 1989-1994
and 5.1 mo (95%CI: 4.3-5.9 mo) in 2010-2014. One-year OS rate was 12% (95%CI: 6%-
20%) in 1989-1994 and 23% (95%CI: 17%-29%) in 2010-2014.
DISCUSSION
In  the  Netherlands,  median  OS  of  patients  with  proximal  esophageal  cancer
significantly increased by approximately two mo between 1989 and 2014. In patients
with non-metastatic proximal esophageal cancer, 5-year OS almost tripled to 13% in
2010-2014,  although the absolute longterm outcome remains poor.  Multivariable
analysis showed that improvements in treatment over time might have led to this
survival benefit. The improvement is likely to be attributable to the implementation of
CRT in the late nineties,  accounting for almost 50% of treatment choices in non-
metastatic proximal esophageal cancer nowadays. The proportion of patients who did
not receive any anti-cancer treatment remained remarkably high, being one in five
patients  with  non-metastatic  and one  in  four  patients  with  metastatic  proximal
esophageal cancer, which may be a reflection of the poor performance status of these
patients.
We observed that in the patients with non-metastatic proximal esophageal cancer
(n = 2194), the median OS improved from 8 mo in 1989-1994 to 13 mo in 2010-2014,
with  comparable  OS between CEC and UTEC.  Considering  OS in  patients  with
metastatic disease did not improve significantly over time, stage migration was not
expected to be a major contributor to the improved survival in the non-metastatic
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Figure 2
Figure 2  Overall survival by 5-year period of diagnosis of patients with proximal esophageal cancer in the
Netherlands between 1989 and 2014, irrespective of stage at diagnosis.
group. A Surveillance, Epidemiology, and End Results (SEER) data-based study in
362 patients with non-metastatic CEC diagnosed between 1998 and 2008 showed a
longer median OS, i.e., 14 mo[12]. The shorter median survival observed in our study
may partly  be  explained by the  inclusion of  patients  with  a  history  of  previous
malignancies,  whereas  the  SEER  data-based  study  excluded  these  patients.  In
addition,  we included patients  with  unknown metastatic  status  in  the  group of
patients with non-metastatic disease, which could have lead to an underestimation of
the OS in the non-metastatic patient group.
Our study showed a reduction of surgical approaches from 23% in the earliest time
period to 10% in the most recent period. The aforementioned SEER population-based
study showed similar results, where only 11% of patients with cervical esophageal
cancer  underwent  surgery  and 79% radiotherapy (chemotherapy data  were  not
available)[12].  These findings confirm a different  approach in the management of
proximal esophageal cancer in specific as compared with cancers from all sites of the
esophagus.  In  the  latter  group  the  proportion  of  patients  treated  with  surgery
remained  relatively  stable  over  time,  from 25% between  1989  and 2004,  to  29%
between 2010 and 2014[2].
Considering bias by indication,  we hypothesized that  patients with resectable
tumors, undergoing surgery, might show a superior outcome when compared with
CRT. However, in the current population-based study, we observed a comparable OS
in  patients  treated  with  surgery  vs  those  treated  with  definitive  CRT  which  is
consistent with a recent observational study in 148 patients with cervical esophageal
cancer[13].  The current study showed that period effect in the multivariable model
disapeared  after  including  treatment  modality.  These  findings  suggest  that
improvements in the (non-surgical) treatment had a substantial effect on the observed
improvement in OS. However progress in OS may also have partly occurred due to
advancements in the management of non-cancer related high mortality disorders, e.g.,
cardiovascular disease[14]. Figures from Statistics Netherlands show that the remaining
life expectancy for, for example, an average 65 year old person was 17 years in 1989
and 20 years in 2014[15]. Whether this increase in life expectancy is also seen in the
high-risk population presented in our study is unknown.
In patients with metastatic proximal esophageal cancer, we did not observe any
significant improvements in OS over time. These findings are in contrast to previous
population-based studies, observing an increased survival over the years in the total
group of  patients  with  metastatic  esophageal  cancer  patients,  including  10% of
cancers originating from the proximal esophagus[16,17]. This difference in the trend in
OS may be explained by the more prominent increased use of systemic therapy in
metastatic  adenocarcinomas[2],  which are  more common in the distal  part  of  the
esophagus[18]. For example, in patients with HER2 amplified adenocarcinomas of the
distal  esophagus,  HER2  directed  therapies  have  led  to  a  survival  benefit[19].  In
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Figure 3
Figure 3  Overall survival by 5-year period of diagnosis of patients with proximal esophageal cancer in the
Netherlands between 1989 and 2014. A: Patients with non-metastatic proximal esophageal cancer; B: Patients with
metastatic proximal esophageal cancer.
metastatic  SCC, palliative systemic therapy is  scarcely applied[2].  A recent meta-
analysis, however, showed that systemic therapy in patients with metastatic SCC
improved OS and quality of life, and is considered standard of care[20]. The outcomes
of  patients  with  metastatic  SCC is  expected  to  improve  in  the  coming  decades,
because the pace of development of cancer immunotherapies is accelerating. Recent
studies show clinical evidence of efficacy of immune checkpoint inhibitors in SCC of
the esophagus[21,22], and are expected to be approved for implementation in clinical
practice.
Furthermore, since proximal esophageal cancer is extremely rare, development of
high-volume expert centers is challenging. Centralization of surgery in esophageal
cancer has led to an increased survival in resectable esophageal cancer[23]. A recent
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Table 2  Univariable and multivariable hazard ratios for overall survival of patients diagnosed with non-metastatic proximal esophageal
cancer (n = 2194)
Charactistics n
Univariable analysis Multivariable analysis Multivariable analysis1
HR (95%CI) P value HR (95%CI) P value HR (95%CI) P value
Period
1989-1994 405 Ref. Ref. Ref.
1995-1999 411 0.92 (0.80-1.05) 0.21 0.91 (0.79-1.05) 0.18 0.85 (0.74-0.98) 0.03
2000-2004 456 0.92 (0.81-1.06) 0.24 0.97 (0.85-1.12) 0.71 0.94 (0.82-1.08) 0.39
2005-2009 448 0.73 (0.63-0.83) < 0.001 0.77 (0.67-0.89) < 0.001 0.88 (0.76-1.02) 0.09
2010-2014 474 0.59 (0.51-0.68) < 0.001 0.72 (0.62-0.85) < 0.001 0.94 (0.79-1.10) 0.43
Age
< 60 yr 562 Ref. Ref. Ref.
60-74 yr 1002 1.06 (0.95-1.18) 0.30 1.11 (0.99-1.23) 0.08 0.97 (0.86-1.08) 0.53
≥ 75 yr 630 1.50 (1.33-1.69) < 0.001 1.51 (1.34-1.71) < 0.001 1.00 (0.87-1.14) 0.95
Histology
SCC 1797 Ref. Ref. Ref.
AC 242 1.07 (0.93-1.23) 0.37 0.97 (0.84-1.12) 0.64 0.88 (0.76-1.02) 0.09
Other 155 1.47 (1.24-1.74) < 0.001 1.22 (1.03-1.44) 0.02 1.11 (0.93-1.31) 0.25
Tumor location
UTEC 1672 Ref. Ref. Ref.
CEC 522 0.97 (0.88-1.08) 0.59 0.89 (0.80-0.98) 0.02 0.95 (0.86-1.06) 0.37
cT category
cT1-3 642 Ref. Ref. Ref.
cT4 506 2.03 (1.79-2.30) < 0.001 1.93 (1.69-2.19) < 0.001 1.62 (1.42-1.85) < 0.001
cTx 1046 1.75 (1.57-1.94) < 0.001 1.50 (1.33-1.69) < 0.001 1.25 (1.11-1.41) < 0.001
cN category
cN0 825 Ref. Ref. Ref.
cN+ 811 1.29 (1.16-1.43) < 0.001 1.44 (1.29-1.60) < 0.001 1.35 (1.21-1.50) < 0.001
cNx 558 2.06 (1.84-2.30) < 0.001 1.78 (1.59-2.00) < 0.001 1.37 (1.22-1.55) < 0.001
Treatment
No localized treatment 538 Ref. Ref.
Resection 183 0.19 (0.16-0.22) < 0.001 0.22 (0.18-0.26) < 0.001
Neoadjuvant and resection 126 0.15 (0.12-0.18) < 0.001 0.17 (0.13-0.21) < 0.001
Radio- and chemotherapy 480 0.17 (0.14-0.19) < 0.001 0.19 (0.16-0.22) < 0.001
Chemotherapy 67 0.38 (0.29-0.49) < 0.001 0.39 (0.30-0.50) < 0.001
Radiotherapy 800 0.38 (0.34-0.42) < 0.001 0.40 (0.36-0.46) < 0.001
1Additionally adjusted for treatment category. SCC: Squamous cell carcinoma; AC: Adenocarcinoma; CEC: Cervical esophageal cancer; UTEC: Upper
thoracic esophageal cancer; HR: Hazard ratio; CI: Confidence interval.
Dutch study showed that center volume of palliative systemic therapy for metastatic
esophagogastric cancer was associated with improved survival, suggesting a volume-
outcome  relationship [24].  Giving  the  low  incidence  rate  and  the  challenging
performance status of these patients, this could be a plea for centralization of care for
patients with proximal esophageal cancer.
The retrospective nature of this study is inherent with some limitations mainly
attributable  to  the  availability  of  information.  Coding  of  the  tumor  was  being
performed on the basis of topography, extracted from the medical records depending
on  input  of  physicians  and  interpretation  of  administrators,  posing  a  risk  of
misclassification. The NCR does not include information on treatment techniques,
schedules, and its related toxicities, causing interpretation adversity. Furthermore,
data  regarding  risk  factors,  e.g.,  smoking  behaviour  and  alcohol  consumption,
comorbidity,  performance  status,  and  disease  specific  cause  of  death  were  not
available, resulting in a risk of residual confounding. However, our multivariable
model showed that the period effect almost completely dissapeared after including
treatment modalities to the multivariable model, implicating that there are no major
confounders missing.
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The  strength  of  our  study  is  that  it  is  a  large  population-based  cohort.  This
nationwide cohort of patients with proximal esophageal cancer in the Netherlands
represents daily clinical practice, reflecting real-life treatment and survival. Moreover,
the follow-up period can be considered long, given the relatively short survival time
of patients with proximal esophageal cancer.
In conclusion, this nationwide study in patients with proximal esophageal cancer
showed an increasing use of definitive CRT over the study period, with improved
survival in non-metastatic disease, although long-term result is still rather poor.
ARTICLE HIGHLIGHTS
Research background
Proximal esophageal cancer is a rare disease, accounting for only 10% of all esophageal cancers.
Nearby vital structures are involved in almost all proximal esophageal cancers at diagnosis, and
as such surgical treatment is mutilating with major implications for quality of life of patients.
Definitive chemoradiation (CRT) is an alternative treatment option, but survival data are scarce,
restricting patient counseling.
Research motivation
To optimize treatment strategies and counseling of patients with proximal esophageal cancer, it
is therefore essential to gain more insight in patient characteristics, provided therapies and
outcome through real-life studies.
Research objectives
The aim of this population-based cohort study was to establish the trends in treatment and
overall  survival  (OS)  in  patients  diagnosed  with  non-metastatic  or  metastatic  proximal
esophageal cancer in a nationwide registry between 1989 and 2014.
Research methods
All patients with a tumor located in the cervical or upper thoracic esophagus diagnosed between
1989  and  2014  were  identified  in  the  Netherlands  Cancer  Registry  (NCR).  The  NCR  is  a
population-based cancer registry of all residents of the Netherlands. Trends in radiotherapy,
chemotherapy, and surgery, and OS were assessed. Analyses were stratified by presence of
distant metastasis. Multivariable Cox proportional hazards regression analyses was performed
to assess the effect f  period of diagnosis on OS, adjusted for adjust for patient,  tumor, and
treatment characteristics.
Research results
Median  OS  of  patients  with  proximal  esophageal  cancer  significantly  increased  by
approximately  two mo between  1989  and  2014.  In  patients  with  non-metastatic  proximal
esophageal cancer, 5-year OS almost tripled to 13% in 2010-2014, although the absolute longterm
outcome remains poor. Multivariable analysis showed that improvements in treatment over time
have  led  to  this  survival  benefit.  The  improvement  is  likely  to  be  attributable  to  the
implementation of CRT in the late nineties, accounting for almost 50% of treatment choices in
non-metastatic  proximal  esophageal  cancer  nowadays,  as  shown in  the  current  study.  In
metastatic disease, median OS did not change significantly between 1989 and 2014.
Research conclusions
Surgical treatment for proximal esophageal cancer has been substituted by definitive CRT in the
more recent years, and was likely to be associated with significant survival improvement of
patients with non-metastatic proximal esophageal cancer. (Long-term) survival data of patients
with (non-)metastatic proximal esophageal cancer are provided from a large national database,
representing daily clinical practice.
Research perspectives
Our findings give insights in real-life survival of patients with proximal esophageal cancer,
providing crucial support for patient counseling. Future research should focuss on outcome
between different CRT regimens, to optimize non-surgical treatment.
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